This half-day continuing education symposium will explore the basic science and recent clinical research on fibroid treatment with selective progesterone receptor modulators (SPRMs). The goal of the symposium will be to develop a management algorithm that includes surgical, non-surgical, and medical approaches for the management of symptomatic uterine fibroids. Attendees will hear from a slate of experts in the field and will have the opportunity to ask questions during the Q&A sessions.
PROGRAM
Continuing Education Credit
The North American Menopause Society (NAMS) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other healthcare professionals who participate in this activity will receive a certificate of participation.
Learning Objectives
By participating in this live activity, attendees should be able to
- Understand the underlying biology of uterine fibroid growth.
- Become familiar with the pharmacodynamics of selective progesterone receptor modulators.
- Identify conservative options for treatment of uterine fibroids.
- Develop treatment algorithms for the management of excessive uterine bleeding due to uterine fibroids
- Compare and contrast the evidence-based information on medical treatment options for uterine fibroids.
Acknowledgement of Support
This CME activity is supported by grant funding from Allergan
Registration
Registration for the symposium will open in June
Attendees of the Translational Science Symposium are encouraged to stay on and attend the NAMS 2018 Annual Meeting, convening October 3 to October 6.